

# Adolfo Favaretto

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1521372/adolfo-favaretto-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

87  
papers

3,927  
citations

28  
h-index

61  
g-index

90  
ext. papers

4,468  
ext. citations

5.5  
avg. IF

4.29  
L-index

#	Paper	IF	Citations
87	Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study.. <i>European Journal of Cancer</i> , <b>2022</b> , 167, 81-91	7.5	0
86	Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covid19 study. <i>European Journal of Cancer</i> , <b>2021</b> , 147, 120-127	7.5	8
85	A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 80-90	8.9	26
84	From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for -Positive Non-Small Cell Lung Cancer (MOST Study). <i>Oncologist</i> , <b>2019</b> , 24, e318-e326	5.7	3
83	The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 994-1002	6.1	17
82	NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 799-811	21.7	44
81	Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 342-349	2.2	70
80	Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy. <i>Current Clinical Pharmacology</i> , <b>2018</b> , 13, 76-84	2.5	5
79	A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1101	5.6	4
78	Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. <i>Future Oncology</i> , <b>2018</b> , 14, 1347-1354	3.6	7
77	LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3316-3324	12.9	28
76	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , <b>2017</b> , 5, 435-444	35.1	133
75	HLA-G 3TJTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	9
74	Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. <i>Oncotarget</i> , <b>2017</b> , 8, 32626-32638	3.3	14
73	EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer. <i>Anticancer Research</i> , <b>2017</b> , 37, 2457-2464	2.3	2
72	Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 97, 220-30	7	35
71	Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. <i>Lung Cancer</i> , <b>2016</b> , 100, 30-37	5.9	3

70	Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman. <i>Lung Cancer</i> , <b>2016</b> , 96, 52-5	5.9	7
69	Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization. <i>Oncotarget</i> , <b>2016</b> , 7, 25050-63	3.3	6
68	Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment. <i>OncoTargets and Therapy</i> , <b>2016</b> , 9, 3671-81	4.4	2
67	Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer. <i>BMC Cancer</i> , <b>2016</b> , 16, 312	4.8	17
66	Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2667-74	2.2	200
65	Treatment of Unfit Patients With Advanced Non-Small-Cell Lung Cancer: Definition Criteria According an Expert Panel. <i>Clinical Lung Cancer</i> , <b>2015</b> , 16, 399-405	4.9	17
64	Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 665-72	8.9	22
63	Results of surgical resection after induction chemoradiation for Pancoast tumours □ <i>Interactive Cardiovascular and Thoracic Surgery</i> , <b>2015</b> , 20, 805-11; discussion 811-2	1.8	14
62	Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature. <i>American Journal of Case Reports</i> , <b>2015</b> , 16, 782-9	1.3	7
61	MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data. <i>Oncotarget</i> , <b>2015</b> , 6, 42053-66	3.3	9
60	Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer. <i>Anticancer Research</i> , <b>2015</b> , 35, 2183-9	2.3	2
59	Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2014</b> , 15, 166-70	4.9	24
58	Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2014</b> , 15, 1379-88	21.7	103
57	Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 study. <i>Lung Cancer</i> , <b>2014</b> , 86, 47-53	5.9	
56	Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2014</b> , 140, 1783-93	4.9	7
55	Valutazione economica in base allo studio NAVoTRIAL01 con riferimento al contesto sanitario italiano: Vinorelbine orale e Cisplatino o Pemetrexed e Cisplatino seguiti da mantenimento rispettivamente con Vinorelbine orale e Pemetrexed nel trattamento del Carcinoma Polmonare Non a Piccole Cellule Non Squamoso (NS-NSCLC) in stadio avanzato. <i>Pharmacoeconomics Italian</i>		2
54	Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey. <i>British Journal of Cancer</i> , <b>2014</b> , 111, 220-6	8.7	28
53	A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. <i>Nature Genetics</i> , <b>2014</b> , 46, 844-9	36.3	130

52	Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01). <i>Clinical Lung Cancer</i> , <b>2014</b> , 15, 258-65	4.9	16
51	Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 1008-1017	8.9	8
50	Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection. <i>Interactive Cardiovascular and Thoracic Surgery</i> , <b>2014</b> , 19, 256-62; discussion 262	1.8	14
49	Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4647-59	12.9	93
48	Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 733-7	8.9	24
47	Platinum drugs and DNA repair mechanisms in lung cancer. <i>Anticancer Research</i> , <b>2014</b> , 34, 493-501	2.3	44
46	Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 552-8	8.7	75
45	An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma. <i>Cancer Treatment Reviews</i> , <b>2013</b> , 39, 10-7	14.4	18
44	Effects of sulfonylureas on tumor growth: a review of the literature. <i>Oncologist</i> , <b>2013</b> , 18, 1118-25	5.7	38
43	Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2013</b> , 44, 104-10	3	2
42	The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. <i>Oncotarget</i> , <b>2013</b> , 4, 1572-81	3.3	18
41	Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1830-1844	8.9	17
40	Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 233-42	8.9	4
39	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3002-11	2.2	193
38	Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. <i>BMC Research Notes</i> , <b>2012</b> , 5, 482	2.3	30
37	Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials. <i>Lung Cancer</i> , <b>2012</b> , 76, 457-64	5.9	14
36	Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM). <i>Anticancer Research</i> , <b>2012</b> , 32, 5393-9	2.3	5
35	Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience. <i>Lung Cancer</i> , <b>2011</b> , 73, 351-5	5.9	10

34	Role of genotyping in non-small cell lung cancer treatment: current status. <i>Drugs</i> , <b>2011</b> , 71, 2231-46	12.1	17
33	Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1528-1534	10.3	42
32	Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer. <i>Current Drug Targets</i> , <b>2011</b> , 12, 922-33	3	24
31	Effect of induction chemotherapy on lung function and exercise capacity in patients affected by malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2010</b> , 37, 1464-9	3	10
30	Preoperative concomitant chemo-radiotherapy in superior sulcus tumour: A mono-institutional experience. <i>Lung Cancer</i> , <b>2010</b> , 68, 228-33	5.9	5
29	Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. <i>Anticancer Research</i> , <b>2010</b> , 30, 5121-8	2.3	35
28	Second and third line treatment in non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 71, 117-26	7	7
27	Molecular targets in malignant pleural mesothelioma treatment. <i>Current Drug Targets</i> , <b>2009</b> , 10, 1235-44		22
26	Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 51-6	8.7	93
25	Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. <i>Lung Cancer</i> , <b>2008</b> , 60, 240-5	5.9	21
24	Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4663-9	2.2	70
23	Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, 221-9	8.9	38
22	Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEMcitabine-COxib in NSCLC (GECO) study. <i>Lancet Oncology</i> , <b>2007</b> , 8, 500-12	21.7	80
21	Long-term results of surgical management of pulmonary metastases from renal cell carcinoma. <i>Thoracic and Cardiovascular Surgeon</i> , <b>2006</b> , 54, 544-7	1.6	30
20	Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 1443-8	2.2	224
19	Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 681-7	2.2	49
18	Overview on ongoing or planned clinical trials in Europe. <i>Lung Cancer</i> , <b>2005</b> , 49 Suppl 1, S117-21	5.9	16
17	Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6815-22	2.2	394

16	Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 569-75	2.2	77
15	Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease. <i>Acta Haematologica</i> , <b>2004</b> , 112, 141-7	2.7	9
14	Long-term survival and prognostic factors in thymic epithelial tumours. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2004</b> , 26, 412-8	3	105
13	Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. <i>Critical Reviews in Oncology/Hematology</i> , <b>2004</b> , 51, 171-89	7	18
12	Supportive care in patients with advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , <b>2003</b> , 89, 1013-21	8.7	22
11	Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 362-72	9.7	673
10	Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. <i>Melanoma Research</i> , <b>2001</b> , 11, 189-96	3.3	55
9	Long term results of surgery and chemotherapy in small cell lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , <b>1998</b> , 14, 398-402	3	60
8	Ultrarapid high-dose course of prophylactic cranial irradiation in small-cell lung cancer: evaluation of late neurologic morbidity in 16 long-term survivors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1998</b> , 21, 84-90	2.7	16
7	Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer: A phase II trial. <i>Cancer</i> , <b>1996</b> , 78, 1701-1707	6.4	7
6	Epirubicin, methotrexate and bleomycin in the management of recurrent squamous cell head and neck cancer. A GSTTC randomised phase II study. <i>European Journal of Cancer</i> , <b>1993</b> , 29A, 704-8	7.5	6
5	A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1993</b> , 16, 264-7	2.7	6
4	Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics. <i>Cancer</i> , <b>1993</b> , 72, 697-706	6.4	20
3	Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with granulocyte-macrophage colony-stimulating factor. <i>Annals of Hematology</i> , <b>1993</b> , 66, 185-93	3	12
2	Second and third responses to the same induction regimen in relapsing patients with multiple myeloma. <i>Cancer</i> , <b>1991</b> , 68, 975-80	6.4	14
1	Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm. <i>Cancer</i> , <b>1990</b> , 65, 2631-4	6.4	22